News stories about AMAG Pharmaceuticals (NASDAQ:AMAG) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AMAG Pharmaceuticals earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 45.6363573213358 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- Featured Volatile Stock – AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) – The Investor Guide (wallstreetnews24.com)
- AMAG Pharmaceuticals, Inc. (AMAG) – 52-Weeks Low Effect in Stock – The Stocks News (press release) (thestocksnews.com)
- AMAG Pharmaceuticals, Inc. (AMAG) – 52-Week New High Stock to Track – The Stocks News (press release) (thestocksnews.com)
- Digging Deep into the Quant Data For AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Firstgroup plc (LSE:FGP) – Clawson News (clawsonnews.com)
- AMAG Pharmaceuticals Announces Preliminary 2017 Financial Results and Provides 2018 Guidance – GlobeNewswire (press release) (globenewswire.com)
A number of brokerages recently issued reports on AMAG. Piper Jaffray Companies initiated coverage on AMAG Pharmaceuticals in a research report on Monday, October 23rd. They issued a “neutral” rating and a $18.00 price objective on the stock. B. Riley initiated coverage on AMAG Pharmaceuticals in a research report on Thursday, December 7th. They set a “neutral” rating and a $16.00 price target on the stock. Zacks Investment Research upgraded AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. ValuEngine upgraded AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. Finally, Janney Montgomery Scott restated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Tuesday, October 17th. Twelve analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $21.27.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by BBNS and is the property of of BBNS. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-amag-pharmaceuticals-amag-share-price/1808964.html.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with our FREE daily email newsletter.